The company has not filed an annual or quarterly report since its FY2022 10-K, filed Mar 31, 2023. Its latest SEC filing is a 15-12G from Apr 26, 2023.
10-K for FY2022, filed Mar 31, 2023
The sections below describe the company as of the FY2022 annual report.
Develops drug candidates for women's reproductive health, including nolasiban for women undergoing in-vitro fertilization.
10-K for FY2022, filed Mar 31, 2023
Receives upfront payments when it licenses or sells rights to drug candidates, and may receive more if development, regulatory, or sales milestones are met.
10-K for FY2022, filed Mar 31, 2023
$19.6M
10-K for FY2022, filed Mar 31, 2023
$19.6M ↗
Drug companies license or acquire rights to drug candidates: Yuyuan holds a China sublicense for nolasiban, and XOMA bought rights to ebopiprant.
10-K for FY2022, filed Mar 31, 2023
No. It lost $29.9M in FY2022.
10-K for FY2022, filed Mar 31, 2023
Linzagolix exit
ObsEva's earlier development included linzagolix for endometriosis and uterine fibroids; it later terminated the Kissei license after FDA review issues and assigned related development contracts.
20-F for FY2019, filed Mar 5, 2020 10-K for FY2022, filed Mar 31, 2023Linzagolix for the treatment of pain associated with endometriosis and HMB associated with uterine fibroids. We are developing linzagolix…View ↗
Competes with Ferring Pharmaceuticals
10-K for FY2022, filed Mar 31, 2023With respect to nolasiban, there are no other oxytocin receptor antagonists approved either for oral administration or for use in…View ↗
Loading...
